Background: The developmental process of bronchopulmonary dysplasia (BPD) is not identical between very preterm infants born small for gestational age (SGA) and those born appropriate for gestational age (AGA). In this study, we compared the pattern of the inflammatory response in infants of each group, by measuring urinary b2-microglobulin (Ub2M) as an alternative, concise, and less-invasive biomarker.
Significant improvements in premature infant survival have been achieved, but the result is increase in the number of infants at risk of long-term morbidity. [1] [2] [3] Bronchopulmonary dysplasia (BPD), a representative example of such pathophysiology, occurs almost exclusively in very preterm infants and causes major health problems in later life. 4 Particularly, respiratory morbidities of very preterm infants born small for gestational age (SGA) have emerged as an important issue at follow up, because SGA infants comprise a significant percentage of infants admitted to neonatal intensive care units (NICU) 5, 6 due to increasing maternal age and widespread application of assisted reproductive technology, both of which are related to increased risk for preterm birth and SGA. 7 It has been established that an inflammatory process plays a role in the pathogenesis of BPD. 8, 9 Very preterm infants are prone to respiratory distress (requiring supplemental oxygen and mechanical ventilation), fluid overload due to patent ductus arteriosus (PDA), and infection, all of which provoke a systemic inflammatory response. Prior to these factors, very preterm infants are likely exposed to an inflammatory environment already before birth. Intrauterine infection/inflammation, as indicated by placental pathology and increased levels of pro-inflammatory cytokines in the umbilical cord plasma or amniotic fluid, has a strong association with preterm birth and subsequent development of BPD. [10] [11] [12] These findings supporting prenatal inflammation, however, have been less frequently observed in very preterm SGA infants than in very preterm appropriate-for-gestational-age (AGA) infants, because an early manifesting fetal growth impairment is mainly caused by pregnancy-associated vascular disorders, most notably pre-eclampsia, rather than by intrauterine infection/inflammation. 13 In addition, preterm delivery before spontaneous onset of labor is often carried out to prevent both fetal and maternal conditions from deteriorating. Thus, we hypothesized that the pattern of inflammatory response in very preterm SGA infants who later developed BPD would differ from that in very preterm AGA infants with BPD. Moreover, monitoring the intensity of the inflammatory response after preterm birth can provide useful information to identify infants at ongoing risk for the development of BPD, even in the absence of clinical signs of antenatal infection/inflammation.
We previously showed that measurement of urinary b2-microglobulin (Ub2M) excretion can be used as an alternative and concise inflammatory indicator for the prediction of BPD in preterm infants born after pregnancies complicated with placental chorioamnionitis (CAM). [14] [15] [16] The aim of this study was therefore to investigate the pattern of the inflammatory response by measuring Ub2M in very preterm SGA infants with BPD and to compare it with that of very preterm AGA infants with BPD in the context of the developmental process of lung injury.
Methods

Study design
Urinary b2M was measured in very preterm (24-31 weeks of gestational age) singleton infants who were admitted to the NICU at Japanese Red Cross Maternity Hospital between January 2011 and December 2015, and trends were compared between SGA and AGA infants who later developed BPD. The clinical characteristics of the infants and their mothers were retrospectively assessed by review of medical records. Excluded were infants with major congenital anomalies, severe intraventricular hemorrhage (IVH; grades III and IV), and culture-proven sepsis with onset before 72 h of age. Infants who were given postnatal corticosteroids within the first 28 days of age were also excluded from the study. A total of 168 very preterm infants were enrolled with informed consent obtained from the family members of each infant. This study was approved by the Institutional Review Board.
Urinary b2-microglobulin
Spontaneous voided urine samples were obtained from each infant at birth (within 48 h) and at 4 weeks of age using a urine collection bag or by squeezing urine from cotton balls placed in diapers. Urine samples with pH <5.5 were not used because b2M is known to be unstable in strongly acidic urine. Ub2M was assayed using the latex agglutination reaction and corrected against the urine creatinine values of the same samples.
Diagnosis of BPD and other maternal/neonatal morbidities
Bronchopulmonary dysplasia was defined as oxygen dependence ≥28 days after birth plus 36 weeks of postmenstrual age (PMA) and/or a need for any form of positive-pressure respiratory support, compatible with the US National Institutes of Health Workshop consensus definition of moderate and severe grade. 17 The policy of respiratory management was as follows: tracheal intubation and mechanical ventilation were started in neonates without or having inadequate respiratory effort, and surfactant replacement therapy was carried out when the required fractional inspired oxygen was ≥0.3 to maintain hemoglobin oxygen saturation of 90% measured on pulse oximetry (SpO 2 ), even after positive-pressure ventilation was initiated. The need for supplemental oxygen was determined by continuous monitoring on pulse oximetry with the alarm set at 90%.
Maternal and neonatal variables were extracted from the medical records to determine factors contributing to the development of BPD. Complications and interventions during pregnancy, such as preterm premature rupture of the membranes (P-PROM), pregnancy-induced hypertension (PIH), and antenatal glucocorticoid treatment (AGT), were analyzed. Neonatal demographics (gestational weeks at birth and birthweight) and relevant comorbidities, such as symptomatic PDA and episodes of significant infection during the neonatal period (neonatal infection) were analyzed. Gestational age was based on maternal menstrual history or early prenatal ultrasound. SGA was defined as <10th percentile of both weight and height at birth for gestational age based on standards of birth size for Japanese neonates.
18 P-PROM was diagnosed on clinical confirmation of amniorrhexis >24 h before birth. PIH was defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mmHg in repeated measurements in a formerly normotensive mother, according to the international guidelines. 19 Placentas of all mothers were histologically examined, and CAM was diagnosed on polymorphonuclear cell infiltration into the chorionic plate of the placental membrane. Symptomatic PDA was limited to neonates who required medical/ surgical closure after they were diagnosed based on echocardiography.
Neonatal infection was defined as serum C-reactive protein ≥1.0 mg/dL in association with clinical symptoms such as refractory apnea, thermal instability, and poor peripheral perfusion, prompting initiation of i.v. antibiotic treatment.
Statistical analysis
Urinary b2M is presented as median (IQR). Group comparisons of continuous variables were analyzed using MannWhitney U-test. Categorical variables were analyzed using Fisher's exact test. P < 0.05 was considered significant.
Results
Clinical characteristics
There were 168 singleton very preterm infants during the study period. Of these, three infants died before 36 weeks' PMA, five infants were transferred for surgery, and two infants were diagnosed with severe grade IVH. Collection of paired urinary specimens at birth and at 4 weeks of age failed in 12 infants. Data on the remaining 146 very preterm infants (gestational age, 28.8 AE 2.0 weeks; birthweight, 1,205 AE 341 g) were available for the analysis.
Thirty-three infants were SGA (gestational age, 29.1 AE 1.7 weeks; birthweight, 979 AE 253 g), and 113 were AGA (gestational age, 28.6 AE 2.1 weeks; birthweight, 1,272 AE 335 g). A total of 57 infants (39%) developed BPD; of these 18 were SGA and 39 were AGA. Tables 1,2 compare the maternal and neonatal clinical characteristics of the SGA BPD, AGA BPD, and no-BPD infants. There were no significant differences in mean gestational age or rate of AGT between SGA BPD and AGA BPD infants. SGA BPD infants had a significantly greater incidence of PIH and significantly lower incidences of P-PROM and CAM than AGA BPD infants. Neonatal variables, such as surfactant replacement therapy, symptomatic PDA, and neonatal infection, were similar between SGA and AGA BPD infants.
Urinary b2-microglobulin
At birth, median Ub2M in the no-BPD, SGA BPD, and AGA BPD infants was 6.5 9 10 4 lg/gCr (IQR, 3.4-11.8 9 10 4 lg/ gCr), 7.2 9 10 4 lg/gCr (IQR, 4.0-11.3 9 10 4 lg/gCr), and 12.7 9 10 4 lg/gCr (IQR, 9.1-18.3 9 10 4 lg/gCr), respectively. Ub2M was significantly higher in AGA BPD infants than in SGA BPD and no-BPD infants. At 4 weeks of age, median Ub2M in the no-BPD, SGA BPD, and AGA BPD infants was 5.0 9 10 4 lg/gCr (IQR, 1.6-8.7 9 10 4 lg/gCr), 10.9 9 10 4 lg/gCr (IQR, 4.5-16.2 9 10 4 lg/gCr), and 12.1 9 10 4 lg/gCr (IQR, 8.5-16.3 9 10 4 lg/gCr), respectively. Ub2M in SGA BPD infants and AGA BPD infants was increased to similar levels, but Ub2M in no-BPD infants decreased and was significantly lower than at birth (Fig. 1) .
Discussion
In the present study, the pattern of Ub2M excretion in very preterm SGA infants with BPD was different from that of very preterm AGA infants with BPD. At birth, the Ub2M level in very preterm SGA BPD infants was similar to that in the no-BPD control group, but it increased with time. In contrast, the Ub2M level in very preterm AGA BPD infants was already higher at birth than in the no-BPD control group, and was sustained at 4 weeks of age (Fig. 1) .
Urinary b2M is usually used for the assessment of renal tubular function but, given that b2M is a structural component of the class I major histocompatibility complex (MHC), which is upregulated by systemic immune activation or excess cell turnover, increased levels of this low-molecular-weight protein in the serum and urine have also been reported to be a nonspecific but sensitive indicator of various conditions, such as systemic infection, malignancy, and autoimmune and chronic inflammatory disorders. [20] [21] [22] [23] Given this, we previously reported that elevated Ub2M at birth can be used as an alternative marker of the intrauterine inflammatory response and subsequent risk of BPD in premature infants. [14] [15] [16] In this study, very preterm AGA BPD infants had significantly elevated Ub2M at birth, as well as a higher incidence of placental CAM than very preterm SGA BPD infants and the no-BPD control group. This was consistent with our previous report, suggesting that prenatal exposure to an inflammatory environment was responsible for the subsequent lung injury in this patient group.
In the present study, Ub2M was measured at 4 weeks of age, yielding new findings about the trends of this surrogate inflammatory marker during the neonatal period by patient group. Ub2M in the no-BPD control group decreased with time, which was considered to reflect the physiological maturation of renal tubular function.
Urinary b2M in very preterm infants who later developed BPD, regardless of AGA or SGA status, however, did not decrease or was even higher at 4 weeks of age than at birth. This implies that very preterm infants with BPD experience inflammatory stimuli for a long period after birth. The incidence of surfactant replacement therapy in both very preterm AGA and SGA infants with BPD was higher but not significantly different compared with the no-BPD control group, probably because early surfactant instillation was the management policy to obtain respiratory stabilization of ventilated preterm infants. Nevertheless, the subsequent incidence rates of symptomatic PDA necessitating medical/surgical closure and neonatal infections were significantly higher in both very preterm AGA and SGA infants with BPD than in the no-BPD control group ( Table 2 ). All of these postnatal factors are well established as triggering events to provoke a systemic inflammatory response.
Together with these postnatal factors, synergistic and additive effects of prenatal factors have been generally accepted in explaining the complex process of the development of BPD. 8, 24 Because CAM is the leading cause of very preterm birth, prenatal exposure to infection/inflammation has been suggested to prime the immature lung to be more vulnerable to inflammatory stimuli after birth. 25, 26 Furthermore, it was reported that not CAM alone, but a combination of CAM and prolonged ventilation and postnatal sepsis, did increase the risk for BPD. 27 In the present study, despite the similar incidence rates of postnatal factors, there was a sharp contrast in the prevalence of P-PROM, CAM, and PIH between very preterm AGA and SGA infants with BPD. Therefore, a pregnancy-associated vascular disorder rather than intrauterine infection/ inflammation was considered to sensitize the fetal lung to postnatal inflammatory stimuli in very preterm SGA infants with BPD, whose Ub2M was not increased at birth but was increased at 4 weeks of age. Abnormal angiogenesis has been suggested to be a common feature in the pathogenesis of PIH and fetal growth restriction due to placental insufficiency. Processes that limit fetal growth and maturation may also limit those of the fetal lung, manifesting after birth as reduced secretion of surfactant protein, increased airway resistance, or pulmonary hypertension. 28 Indeed, an imbalance between angiogenic and anti-angiogenic factors derived from endothelial dysfunction was observed not only in the plasma of (20) women with pre-eclampsia, but also in the tracheal aspirates of the infants with BPD: reduced expression of vascular endothelial growth factor (VEGF), concurrent with higher levels of its soluble receptor (also known as soluble fms-like tyrosine kinase-1) is predictive of BPD in ventilated very low-birthweight infants. 29 Thus, a systemic inflammatory response would appear to begin not immediately after birth, but several weeks later, as observed in the trend of Ub2M in very preterm SGA infants with BPD in the present study.
Several potential limitations of this study should be taken into account. The first is the relatively small number of patients in a single center and the retrospective design. Second, pro-inflammatory cytokines were not measured, and their relationships with Ub2M were not evaluated in each patient group. We had, however, already assessed the value of measuring neonatal Ub2M in comparison with umbilical cord blood interleukin-6 in premature infants at risk of developing BPD. 16 Therefore, we proposed that applying this concise and less-invasive laboratory test as a surrogate inflammatory marker could be helpful to identify infants with ongoing risk for the development of BPD, particularly in SGA infants without verified placental CAM.
In conclusion, different patterns of Ub2M during the neonatal period were observed between very preterm SGA and AGA infants with BPD. Given that the prevalence of postnatal risks was similar, the prenatal environment other than infection/inflammation was considered to sensitize the fetal lung to become more vulnerable to postnatal factors in very preterm SGA infants with BPD. Recording the trends of Ub2M could be helpful to identify very preterm infants with ongoing risk for the development of lung injury, even in the absence of placental CAM. *P < 0.05; **P < 0.01; †SGA BPD vs AGA BPD; ‡vs no BPD. AGA, appropriate for gestational age; BPD, bronchopulmonary dysplasia; PDA, patent ductus arteriosus; SGA, small for gestational age. Fig. 1 Urinary b2-microglobulin (Ub2M) at (a) birth and (b) 4 weeks of age vs bronchopulmonary dysplasia (BPD) and birth size status. Whiskers, 10th and 90th percentiles; box ends, 25th and 75th percentiles; horizontal line, median. **P < 0.01 ( ‡ vs no BPD at birth, # vs SGA BPD at birth, ## vs no BPD at 4 weeks of age). AGA, appropriate for gestational age; SGA, small for gestational age.
